Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 89, Issue , 2015, Pages 259-270

  Tsukigawa, Kenji ^a   Nakamura, Hideaki ^a   Fang, Jun ^a   Otagiri, Masaki ^a   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

Antitumor effect; Intracellular uptake; PEG cleavability; PEG dilemma; PEG ZnPP; Tumor proteases

Indexed keywords

AMIDE; CYSTEINE PROTEINASE; ESTER; ESTERASE; ETHER; MACROGOL; PEGYLATED ZINC PROTOPORPHYRIN; PROTOPORPHYRIN ZINC; SERINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; METALLOPORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADATION; BIOLOGICAL ACTIVITY; CANCER CELL; CHEMICAL BOND; CONJUGATE; CYTOTOXICITY; DRUG RELEASE; DRUG STABILITY; ENZYME BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; THERAPY EFFECT; TISSUE DISTRIBUTION; TISSUE HOMOGENATE; ANIMAL; CHEMICAL REACTION; CHEMISTRY; DRUG DELIVERY SYSTEM; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMICAL PROCESSES; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HT29 CELLS; HUMANS; K562 CELLS; MALE; METALLOPORPHYRINS; MICE; POLYETHYLENE GLYCOLS;

EID: 84920202863     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.12.016     Document Type: Article

References (35)

1. C. Elvira, A. Gallardo, J.S. Roman, and A. Cifuentes Covalent polymer-drug conjugates Molecules 10 2005 114 125
2. A.S. Hoffman The origins and evolution of "controlled" drug delivery systems J. Control. Release 132 2008 153 163
3. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
4. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1990 235 237
5. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomed. 1 2006 297 315
6. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
7. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
8. H. Hatakeyama, H. Akita, K. Kogure, M. Oishi, Y. Nagasaki, Y. Kihira, M. Ueno, H. Kobayashi, H. Kikuchi, and H. Harashima Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid Gene Ther. 14 2007 68 77
9. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160
10. T. Terada, M. Iwai, S. Kawakami, F. Yamashita, and M. Hashida Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting J. Control. Release 111 2006 333 342
11. H. Xu, Y. Deng, D. Chen, W. Hong, Y. Lu, and X. Dong Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives J. Control. Release 130 2008 238 245
12. G.F. Walker, C. Fella, J. Pelisek, J. Fahrmeir, S. Boeckle, M. Ogris, and E. Wagner Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo Mol. Ther. 11 2005 418 425
13. A. Guiotto, M. Canevari, P. Orsolini, O. Lavanchy, C. Deuschel, N. Kaneda, A. Kurita, T. Matsuzaki, T. Yaegashi, S. Sawada, and F.M. Veronese Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin J. Med. Chem. 47 2004 1280 1289
14. T. Ishida, M. Ichihara, X. Wang, K. Yamamoto, J. Kimura, E. Majima, and H. Kiwada Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes J. Control. Release 112 2006 15 25
15. H. Koide, T. Asai, H. Kato, H. Ando, K. Shiraishi, M. Yokoyama, and N. Oku Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles Int. J. Pharm. 432 2012 75 79
16. T. Ishida, and H. Kiwada Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes Int. J. Pharm. 354 2008 56 62
17. S.K. Sahoo, T. Sawa, J. Fang, S. Tanaka, Y. Miyamoto, T. Akaike, and H. Maeda Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity Bioconjug. Chem. 13 2002 1031 1038
18. J. Fang, T. Akaike, and H. Maeda Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment Apoptosis 9 2004 27 35
19. S.M. Keyse, and R.M. Tyrrell Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite Proc. Natl. Acad. Sci. USA 86 1989 99 103
20. K. Doi, T. Akaike, S. Fujii, S. Tanaka, N. Ikebe, T. Beppu, S. Shibahara, M. Ogawa, and H. Maeda Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth Br. J. Cancer 80 1999 1945 1954
21. S. Tanaka, T. Akaike, J. Fang, T. Beppu, M. Ogawa, F. Tamura, Y. Miyamoto, and H. Maeda Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour Br. J. Cancer 88 2003 902 909
22. K. Mitani, H. Fujita, Y. Fukuda, A. Kappas, and S. Sassa The role of inorganic metals and metalloporphyrins in the induction of haem oxygenase and heat-shock protein 70 in human hepatoma cells Biochem. J. 290 Pt3 1993 819 825
23. K. Sato, K. Ito, H. Kohara, Y. Yamaguchi, K. Adachi, and H. Endo Negative regulation of catalase gene expression in hepatoma cells Mol. Cell. Biol. 12 1992 2525 2533
24. M. Mayerhofer, K.V. Gleixner, J. Mayerhofer, G. Hoermann, E. Jaeger, K.J. Aichberger, R.G. Ott, K. Greish, H. Nakamura, S. Derdak, P. Samorapoompichit, W.F. Pickl, V. Sexl, H. Esterbauer, I. Schwarzinger, C. Sillaber, H. Maeda, and P. Valent Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib Blood 111 2008 2200 2210
25. G. Yang, X. Nguyen, J. Ou, P. Rekulapelli, D.K. Stevenson, and P.A. Dennery Unique effects of zinc protoporphyrin on HO-1 induction and apoptosis Blood 97 2001 1306 1313
26. J. Fang, T. Sawa, T. Akaike, T. Akuta, S.K. Sahoo, G. Khaled, A. Hamada, and H. Maeda In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor Cancer Res. 63 2003 3567 3574
27. A.K. Iyer, K. Greish, T. Seki, S. Okazaki, J. Fang, K. Takeshita, and H. Maeda Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation J. Drug Target. 15 2007 496 506
28. H. Nakamura, J. Fang, B. Gahininath, K. Tsukigawa, and H. Maeda Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles J. Control. Release 155 2011 367 375
29. J. Fang, K. Greish, H. Qin, L. Liao, H. Nakamura, M. Takeya, and H. Maeda HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: in vitro and in vivo anticancer effect Eur. J. Pharm. Biopharm. 81 2012 540 547
30. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
31. F.G. Bahar, K. Ohura, T. Ogihara, and T. Imai Species difference of esterase expression and hydrolase activity in plasma J. Pharm. Sci. 101 2012 3979 3988
32. S. Rakash Role of proteases in cancer: a review Biotechnol. Mol. Biol. Rev. 7 2012 90 101
33. J.M. Jessup Cathepsin B and other proteases in human colorectal carcinoma Am. J. Pathol. 145 1994 253 262
34. T. Aboul-Fadl, M. Sheha, A. El-Azab, and H. Abdel-Aziz Amantadine amides prodrugs as hepatic delivery systems to enhance its activity against HCV Dig. J. Nanomater. Biostruct. 6 2011 1675 1683
35. W. Wichitnithad, U. Nimmannit, P.S. Callery, and P. Rojsitthisak Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates J. Pharm. Sci. 100 2011 5206 5218